Will Rivaroxaban Be Cost-Effective for Prevention. of Venous Thromboembolism after Total Hip Replacement in US Patients?.

被引：0
|
作者：
Kwong, Louis [1 ]
Diamantopoulos, Alexander [2 ]
Forster, Fiona [2 ]
Sengupta, Nishan
Lees, Michael [3 ]
机构：
[1] Harbor UCLA Med Ctr, Torrance, CA 90509 USA
[2] IMS Hlth, London, England
[3] Bayer PLC, Uxbridge, Middx, England
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：467 / 467
页数：1
相关论文
共 50 条
  • [21] MODEL SENSITIVITY ANALYSIS OF VENOUS THROMBOEMBOLISM PREVENTION AFTER TOTAL HIP REPLACEMENT
    Vorobiev, P.
    Krasnova, L.
    Shustov, A.
    Bashlakova, E.
    VALUE IN HEALTH, 2012, 15 (07) : A369 - A369
  • [22] Rivaroxaban Versus Enoxaparin For Prevention Of Venous Thromboembolism In Elective Total Hip Replacement: A Retrospective Cohort Study
    Young, Stephanie W.
    Kielly, Jason
    Mathews, Maria
    Furey, Andrew
    Grewal, Kuljit
    Bishop, Lisa D.
    Dillon, Carla
    Lee, Tiffany
    Hawboldt, John
    Twells, Laurie
    BLOOD, 2013, 122 (21)
  • [23] COST-EFFECTIVENESS ANALYSIS OF RIVAROXABAN VERSUS DABIGATRAN AND ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE REPLACEMENT
    Vorobyev, P.
    Krasnova, L.
    Borisenko, O.
    Lukyantseva, D.
    Bashlakova, L.
    VALUE IN HEALTH, 2011, 14 (03) : A41 - A41
  • [24] Cost-effectiveness of venous thromboembolism prophylaxis after total hip replacement
    Caprini, JA
    Arcelus, JL
    Kudrna, JC
    Sehgal, LR
    Oyslender, M
    Maksimovic, D
    MacDougall, A
    PHLEBOLOGY, 2002, 17 (3-4) : 126 - 133
  • [25] Pharmacoeconomic Evaluation of Dabigatran, Rivaroxaban and Apixaban versus Enoxaparin for the Prevention of Venous Thromboembolism After Total Hip or Knee Replacement in Spain
    Antonio Gómez-Outes
    Cristina Avendaño-Solá
    Ana Isabel Terleira-Fernández
    Emilio Vargas-Castrillón
    PharmacoEconomics, 2014, 32 : 919 - 936
  • [26] Pharmacoeconomic Evaluation of Dabigatran, Rivaroxaban and Apixaban versus Enoxaparin for the Prevention of Venous Thromboembolism After Total Hip or Knee Replacement in Spain
    Gomez-Outes, Antonio
    Avendano-Sola, Cristina
    Isabel Terleira-Fernandez, Ana
    Vargas-Castrillon, Emilio
    PHARMACOECONOMICS, 2014, 32 (09) : 919 - 936
  • [27] Rivaroxaban, a new oral anticoagulant for the prevention of venous thromboembolism after elective hip or knee replacement surgery
    Haas, Sylvia
    Kubitza, Dagmar
    Perzborn, Elisabeth
    EJHP PRACTICE, 2010, 16 (05): : 29 - 36
  • [28] Rivaroxaban A Review of its Use for the Prophylaxis of Venous Thromboembolism after Total Hip or Knee Replacement Surgery
    Duggan, Sean T.
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2012, 12 (01) : 57 - 72
  • [29] COST-EFFECTIVENESS OF RIVAROXABAN VERSUS ENOXAPARIN FOR PREVENTION OF VENOUS THROMBOEMBOLISM (VTE) AFTER TOTAL KNEE REPLACEMENT (TKR) IN CHINA
    Chen, X. B.
    Wang, C. Y.
    Eggington, S.
    Zhu, M.
    VALUE IN HEALTH, 2010, 13 (07) : A506 - A506
  • [30] PRACTICAL USE OF APIXABAN IN THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE OR HIP REPLACEMENT
    Lassen, M. R.
    DRUGS OF TODAY, 2012, 48 (04) : 249 - 258
12345